NightHawk Biosciences reported $0.6 million in revenue from process development and $0.1 million from service revenue for the third quarter of 2023. The company had approximately $9.5 million in cash, cash equivalents, and short-term investments as of September 30, 2023.

NightHawk Biosciences reported $0.7 million in revenue from process development, an increase compared to the previous year. The company's net loss was $13.9 million, or $0.53 per share. The company had $18.6 million in cash, cash equivalents, and short-term investments as of June 30, 2023.

NightHawk Biosciences reported $6 million in revenue for Q3 2022, primarily from the sale of ANTHIM to Canada's National Emergency Strategic Stockpile. The company's net loss was $13 million, or $0.51 per share. The company is deprioritizing its oncology programs to focus on biomanufacturing and medical countermeasures.

NightHawk Biosciences reported a net loss of $10.2 million, or ($0.40) per share, for the second quarter of 2022. The company recognized $0.05 million in contract revenue, a decrease compared to the previous year. Despite the financial results, NightHawk is progressing with its biopharmaceutical development and manufacturing capabilities, including the upcoming opening of a biologics manufacturing facility and expansion of its pipeline.

Heat Biologics, Inc. provided strategic, financial, and operational updates for the year ended December 31, 2021. The company highlighted the progress of its clinical programs, including HS-110 for non-small cell lung cancer and PTX-35 for solid tumors, as well as its biomanufacturing capabilities and biodefense initiatives.

Heat Biologics reported a net loss attributable to the company of $7.4 million, or ($0.30) per basic and diluted share, for the quarter ended September 30, 2021. The company had approximately $108.9 million in cash, cash equivalents and short investments as of September 30, 2021.

Heat Biologics reported a net loss of $6.5 million, or ($0.26) per share, for the quarter ended June 30, 2021. The company had $122.5 million in cash, cash equivalents and short investments as of June 30, 2021. They recognized $0.5 million of grant revenue.

Heat Biologics reported a net loss of $8.9 million, or $0.06 per share, and grant revenue of $0.8 million for the third quarter of 2020. The company had $117.3 million in cash and short-term investments as of September 30, 2020, and is advancing its oncology and COVID-19 vaccine programs.